Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Holdings Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Won Jeoung Kim

Kwee Hyun Suh

Chang Hee Park

Young Hoon Kim

Gwan Sun Lee

Eun Young Kim

Tae Hee Ha

Ji Sook Kim

Hee Sook Oh

Young Gil Ahn

In Hwan Bae

Ji Young Song

Nam Du Kim

Moon Sub Lee

Jae Yul Choi

Seung Hyun Jung

Eun Young Byun

Wook Jang

Jung Soo Nam

Min Jeong Kim

Chang Hee Dongho-Villa 203 Park

Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Imidazopyridine derivative compounds and use of same

Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Pyrazole derivative compound and use thereof

A novel imidazopyridine derivative compound and uses thereof are disclosed. An imidazopyridopyridine derivative compound of Chemical Formula 1 having selective inhibitory activity for a fibroblast growth factor receptor (FGFR) and a pharmaceutical composition including the compound are disclosed: 

Imidazopyridopyrimidine derivative compound and use thereof

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Bicyclic derivatives and pharmaceutical composition including the same

Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same

This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

Growing community of inventors

Suwon-si, South Korea

Won Jeoung Kim